NewAmsterdam Pharma Newsroom

NewAmsterdam Pharma(NAMS.US) 10% Shareholder Sells US$4.07 Million in Common Stock

$NewAmsterdam Pharma(NAMS.US)$ 10% Shareholder ForGrowth NAP B.V. sold 157.23K shares of common stock on Dec 18, 19, 2024 at an average price of $25.8641 for a total value of $4.07 million. This

Futu NewsDec 21 05:31

Positive Outlook for NewAmsterdam Pharma Driven by Strong Financial Position and Promising Obicetrapib Trial Results

TipRanksDec 21 01:59

NewAmsterdam Pharma(NAMS.US) 10% Shareholder Sells US$4.86 Million in Common Stock

$NewAmsterdam Pharma(NAMS.US)$ 10% Shareholder ForGrowth NAP B.V. sold 191.76K shares of common stock on Dec 12, 13, 2024 at an average price of $25.3433 for a total value of $4.86 million. This

Futu NewsDec 17 05:20

Menarini Group Announces Positive Topline Data From Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib With Ezetimibe 10 Mg

PR NewswireDec 16 21:40

Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?

BenzingaDec 15 23:00

Press Release: NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dow JonesDec 14 06:16

NewAmsterdam Pharma(NAMS.US) 10% Shareholder Sells US$11.74 Million in Common Stock

$NewAmsterdam Pharma(NAMS.US)$ 10% Shareholder ForGrowth NAP B.V. sold 462.29K shares of common stock on Dec 10, 11, 2024 at an average price of $25.3968 for a total value of $11.74 million. This

Futu NewsDec 13 05:18

Reported Earlier, NewAmsterdam Pharma Prices $416.5M Upsized Public Offering At $24.50/Share to Advance Cardiovascular Treatments

BenzingaDec 12 15:23

NewAmsterdam Pharma Is Maintained at Sector Outperform by Scotiabank

Dow JonesDec 12 00:23 · Ratings

NewAmsterdam Pharma Analyst Ratings

BenzingaDec 12 00:11 · Ratings

Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $47

Futu NewsDec 11 21:31 · Ratings

We're Not Very Worried About NewAmsterdam Pharma's (NASDAQ:NAMS) Cash Burn Rate

Simply Wall StDec 11 20:12

Top 3 Health Care Stocks That May Collapse This Quarter

BenzingaDec 11 19:55

Express News | New Amsterdam Invest NV : Scotiabank Raises Target Price to $47 From $35

BreakingsDec 11 19:36

NewAmsterdam Pharma Reports Positive Phase 3 Results for Obicetrapib in Lowering LDL-C and Reducing Cardiovascular Events

BarchartDec 11 06:18

NewAmsterdam Pharma Commences $300M Public Offering Of Ordinary Shares And Pre-Funded Warrants

BenzingaDec 11 05:35

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

GlobeNewswireDec 11 05:34

Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $46

Futu NewsDec 11 05:31 · Ratings

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

BenzingaDec 11 05:05

Buy Rating on NewAmsterdam Pharma: Promising Phase 3 Results and Increased Price Target

TipRanksDec 11 04:55 · Ratings